Behepan

Quick links to important sections

Behepan

Method of action: Vitamins

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Behepan

Quick Facts: Behepan (Cobalamins)

Property Description
Active ingredient Cyanocobalamin, Hydroxocobalamin
Form Film-coated oral tablet, Solution for injection
Pharmacological class Antianemic preparation, Vitamin B12
Common use Replenishing the essential B12 micronutrient
Legal status Prescription-only medicine (Rx)

Behepan: An Essential Antianemic Preparation

Behepan is a pharmaceutical preparation, trademarked and often supplied as a prescription-only medicine in Nordic countries. It is classified as an antianemic drug belonging to the Vitamin B12 (Cobalamins) pharmacological group. Functioning as a substitution therapy agent, the drug is designed to replenish and maintain the body's store of this vital, water-soluble micronutrient. This class of medicine is clinically recognized for its essential role in maintaining healthy blood and nerve cells and supporting DNA production.

Composition and Forms: Dual-Form B12 Delivery

The active substance in Behepan is a combination product comprising two distinct, yet related, forms of B12: Cyanocobalamin and Hydroxocobalamin. Cyanocobalamin is the stable, widespread synthetic form; while Hydroxocobalamin is a naturally occurring precursor that is often the preferred injectable formulation in Europe due to its enhanced tissue retention. Consequently, Hydroxocobalamin may require less frequent administration when used parenterally.

Behepan is commonly supplied as a film-coated oral tablet or a solution for injection, which facilitates different routes of administration, including oral and parenteral delivery. The tablet form is a conventional release product, a key distinction in its pharmaceutical preparation.

General Purpose: Foundational Support for Blood and Nerve Function

The general purpose of Behepan is to provide the essential cofactor necessary for critical metabolic pathways in the body. The B12 supplied is fundamentally required for DNA synthesis in rapidly dividing cells, and it plays an undisputed role in the maintenance of the myelin sheath for nerve function. This action ensures the support of healthy hematopoiesis (red blood cell formation) and helps preserve overall nervous system stability, thereby addressing the profound effects caused by a lack of this key nutrient.

What side effects are possible with Behepan?

Possible Side Effects and Safety Information

The safety profile for Behepan, which contains cyanocobalamin and hydroxocobalamin, is based on the classification systems used by government regulatory agencies (FDA, EMA, etc.). The potential adverse reactions are formally grouped by the system-organ class they affect and by their reported frequency.

Official Adverse Reaction Categories

Classification Examples of Reactions
Dermatological/Immune System Itching (pruritus), hives (urticaria), transitory exanthema (rash), acne-like rash.
Gastrointestinal System Mild transient diarrhea, stomach discomfort, acid or sour stomach.
Cardiovascular System Pulmonary edema and congestive heart failure.

Frequency and Severity Notes

Adverse effects such as fever, rash, and anaphylaxis are reported as rare events in regulatory documents. Some reactions, including severe hypersensitivity and polycythemia vera, are classified as having an incidence not known, meaning their frequency cannot be estimated from available data. A feeling of swelling of the entire body has also been reported.

Serious Adverse Reactions and Safety Constraints

The official labeling documents certain serious adverse reactions, including the risk of anaphylactic shock and death reported with the injectable preparation. Furthermore, severe and swift optic atrophy is documented in patients with early Leber's disease, making the use of cyanocobalamin contraindicated in this population.

Time-related safety patterns are noted, such as the reporting of pulmonary edema and congestive heart failure early in treatment with the parenteral form, or an acne-like rash appearing with a delayed onset of several weeks. Use is also formally contraindicated in individuals with known sensitivity to cobalt or the vitamin B12 itself.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for the active substances in Behepan, Cyanocobalamin and Hydroxocobalamin, is defined by the high margin of safety associated with Vitamin B12 supplementation.

Documented Overdose Presentations

According to the official prescribing information issued by certain regulatory authorities, overdosage has not been formally reported with Cyanocobalamin Injection, USP, in the context of its use as an antianemic preparation. As a result of this documentation, regulatory sources do not list expected symptoms, clinical manifestations, or specific physiological systems affected by an overdose of the medication. No specific toxic dose level is established in official labeling, and there are no documented population-specific overdose notes regarding increased severity for subpopulations.

Emergency Response and Management

The official regulatory documents do not specify a known toxic syndrome for excess cobalamin. Consequently, no specific emergency response actions or immediate measures, such as specific supportive treatments or mandatory monitoring requirements, are formally mandated in the Overdosage section. The official labeling does not define specific conditions or thresholds for when immediate medical help must be sought solely due to Behepan overexposure, reflecting the lack of reported toxicity. No specific antidote is known for excess cobalamin.

This regulatory position is consistent with the general understanding of B12 as a water-soluble vitamin, where excess amounts are typically excreted by the body.

Therapeutic Uses of Behepan

Quick Facts

  • Therapeutic Focus: Addresses low levels of vitamin B12 in the body.
  • Associated Conditions: Used in the management of pernicious anemia.
  • General Use: Supports overall wellness by maintaining appropriate vitamin B12 status.

Behepan contains cyanocobalamin, a manufactured form of vitamin B12. The primary purpose of this treatment is to help prevent or address states of low vitamin B12 (deficiency). Maintaining adequate levels of this essential vitamin is necessary for typical function of nerve cells and the formation of red blood cells.

The medication is used to support individuals whose body does not absorb enough vitamin B12 from food sources. This may occur in people diagnosed with conditions such as pernicious anemia, which interferes with absorption. It may also be utilized following certain types of surgery or when dietary intake is insufficient.

The clinical intervention aims to restore vitamin B12 status to a desirable range, helping to support the body’s health functions that rely on this nutrient.

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Status

Official regulatory documents define the eligibility and non-eligibility for cobalamin preparations (such as Behepan) based on hypersensitivity, underlying diagnosis, and patient physiological status.

Populations for whom use is Contraindicated

Use is absolutely contraindicated for individuals with a documented history of hypersensitivity or allergic reaction to the active substances (cyanocobalamin or hydroxocobalamin) or to cobalt, a component of the B12 molecule.

Standard and Conditional Eligibility

Allowed Populations: The medicine is intended for patients with a documented Vitamin B12 deficiency arising from malabsorption (e.g., pernicious anemia or post-surgical states) or inadequate dietary intake.

Age-Group and Condition-Based Restrictions

  • Pediatric Use: Parenteral solutions require caution in neonates and premature infants due to the potential risk of toxicity from excipients like benzyl alcohol and aluminum accumulation in those with immature kidney function.
  • Kidney Function: Use in patients with impaired kidney function is restricted, particularly with prolonged injectable administration, due to the documented risk of aluminum toxicity.
  • Pregnancy Status: The medicine is classified as FDA Pregnancy Category C; use is only permitted if the prescribing physician deems it clearly necessary.
  • Folic Acid Status: Use requires definitive diagnosis, as administering B12 without confirming the absence of concurrent folic acid deficiency may mask the progression of severe neurological symptoms.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Behepan (Cobalamins) interactions focuses primarily on substances that reduce its systemic exposure or impair its intended therapeutic effect. No medicinal products are formally listed as contraindicated combinations due to interaction risk.

Exposure Reduction and Therapeutic Impairment

The co-administration of certain medicines may reduce the amount of Cobalamins available to the body. This occurs through two main mechanisms documented in regulatory sources:

Interaction Type Interacting Agents (Examples) Official Outcome
Reduced Absorption H2-receptor blockers, certain anticonvulsants, biguanides (Metformin), neomycin, para-aminosalicylic acid May decrease gastrointestinal absorption of vitamin B12.
Lowered Serum Levels Oral Contraceptives May lead to lowered serum concentrations of Cobalamins.
Impaired Response Chloramphenicol (parenteral form), Folic Acid (high doses) May attenuate or impair the expected hematological response.

Substance Restrictions and Specific Constraints

Prolonged, heavy alcohol intake is noted in regulatory text as potentially causing vitamin B12 malabsorption.

Specific constraints are noted for certain populations and procedures:

  • Renal Impairment: Patients with impaired kidney function who receive prolonged parenteral (injectable) administration face a risk of Aluminum accumulation due to the presence of aluminum in some preparations.
  • Laboratory Tests: Certain antibiotics and antimetabolites may invalidate vitamin B12 diagnostic blood assays, requiring careful timing or consideration of testing methods.

Mechanism of Action

Restoring Cofactor Function for DNA Synthesis

The mechanism of Behepan (Cobalamins) operates by supplying precursors for Methylcobalamin, the essential cofactor for the Methionine Synthase enzyme. This interaction catalyzes the regeneration of Tetrahydrofolate (THF), which is required for the synthesis of DNA precursors. By resolving this metabolic block, the mechanism enables necessary DNA synthesis, which is fundamental for the mitotic division and maturation of rapidly proliferating cells, such as those in the bone marrow.


Preventing Neurotoxic Metabolite Accumulation

Behepan also supplies precursors for 5'-Deoxyadenosylcobalamin, the cofactor for the mitochondrial enzyme L-Methylmalonyl-CoA Mutase (MCM). Activating MCM prevents the accumulation of methylmalonic acid (MMA), a neurotoxic metabolite, and other abnormal fatty acid derivatives. This mechanism is crucial for supporting the lipid/protein synthesis needed to preserve the myelin sheath structure around nerve axons, influencing stable central and peripheral nervous system function.


Mechanistic Synergy of Dual Forms

The combination of Cyanocobalamin and Hydroxocobalamin provides complementary pro-cofactor delivery to sustain these two enzymatic pathways. Hydroxocobalamin is a precursor form that can exhibit a greater affinity for plasma proteins, potentially leading to a more sustained availability of the active cofactors compared to Cyanocobalamin.

Dosage and Administration Information

How Behepan is Used

The administration of Behepan, which contains Cobalamins (Cyanocobalamin and Hydroxocobalamin), follows a strict biphasic protocol. The medication is supplied as a Solution for Injection or an Oral Tablet, defining the two official routes of administration: Intramuscular (IM) or Deep Subcutaneous (SC) injection, and the Oral route. The intravenous (IV) route is specifically restricted for deficiency treatment due to the increased rate of excretion.


Biphasic Dosing and Schedule

Treatment is procedurally divided into an intensive correction phase and a long-term maintenance phase. The initial loading phase typically requires a high-dose, high-frequency schedule, such as 100 micrograms to 1000 micrograms administered via IM/SC injection daily or on alternate days until clinical improvement is achieved.

This is followed by the maintenance phase, where the frequency decreases significantly. This long-term use typically involves the administration of 1000 micrograms monthly via injection or 1 mg daily using the oral tablet. For conditions involving uncorrected malabsorption, maintenance therapy must be continued for life.


Administration Context

The injection solution requires administration by a healthcare professional (doctor or nurse) in a clinical setting. When administering the oral tablet, it is often advised to take it on an empty stomach (e.g., two hours after food) to optimize use. Pediatric dosing schedules mirror the adult protocol, using a daily or alternate-day intensive phase followed by a periodic maintenance dose.

Recent Clinical Evidence

Behepan: Recent Clinical Evidence

Behepan is a brand name for cyanocobalamin (Vitamin B12), a form of B12 replacement therapy. Clinical evidence primarily supports its use in addressing and preventing deficiencies of Vitamin B12 that can affect the blood and nervous systems. This deficiency may be caused by inadequate dietary intake, malabsorption disorders such as pernicious anemia, or certain surgical procedures.

Efficacy in Deficiency

Clinical trials and expert consensus indicate that the principal therapeutic goal of B12 replacement, whether parenteral (injection) or high-dose oral supplementation, is to restore adequate vitamin B12 levels. This action is associated with reversing hematological issues (like megaloblastic anemia) and preventing the progression of neurological complications. For patients with acute or severe manifestations, initial parenteral treatment is often regarded as the primary choice.

  • Neurological Findings: If neurological involvement is present, recovery is generally observed to be slower and less predictable than the correction of hematological parameters.
  • Response Time: With adequate replacement therapy, an increase in the reticulocyte count is typically observed within 5 to 7 days, followed by the resolution of anemia within several weeks.

Comparative Effectiveness and Bioavailability

Studies have investigated the relative effectiveness of different forms and routes of B12 administration. While parenteral administration (injections) remains a standard method, particularly for severe deficiency and malabsorption, some research has suggested that high-dose oral cyanocobalamin may achieve similar long-term effectiveness in correcting serum B12 concentrations for maintenance therapy.

Form of Vitamin B12 Bioavailability Note (Based on research)
Cyanocobalamin (Behepan) Widely used; readily converted into active coenzymes in the body.
Hydroxocobalamin Often preferred for initial parenteral therapy; reported to have longer systemic retention.

Research in Non-Deficiency Conditions

Beyond established deficiency treatment, some research has explored the use of high-dose vitamin B12 in managing various pain conditions, including low back pain and neuralgia. While limited data exists, some trials have reported an association between B12 supplementation and a reduction in pain and improvement in functional outcomes in these specific contexts. Further large-scale, placebo-controlled trials are needed to confirm the efficacy and identify optimal treatment parameters for these non-deficiency indications.

Frequently Asked Questions (FAQ)

Common questions about Behepan (FAQ)


Q: How quickly can someone expect Behepan to start working?

Objective evidence that Behepan is working, such as an increase in the production of new red blood cells (reticulocytes), is typically observed within 5 to 7 days of starting therapy. This measurable response in blood components indicates that the replacement therapy is beginning to correct the underlying deficiency. Clinical improvement in noticeable symptoms may be observed over a longer period than the objective blood changes.


Q: Is Behepan the same as other medicines for the same condition?

Behepan is a combination product that contains two forms of Vitamin B12: Cyanocobalamin and Hydroxocobalamin. Other medicines prescribed for B12 deficiency may contain only one of these forms or a different derivative. The dual-form composition is described in official product information.


Q: Is it common to feel tired when first starting Behepan?

Feeling tired or fatigued is a well-known symptom of Vitamin B12 deficiency itself, which is what Behepan is intended to treat. While fatigue is not listed as a common adverse reaction of the medicine, an improvement in energy is commonly associated with the correction of the underlying deficiency.


Q: Are the side effects of Behepan temporary or do they last?

The duration of side effects can vary. Some reactions, such as mild rash or fever, are described in official documents as transitory, meaning they are short-lived. Other effects, like an acne-like rash, may have a delayed onset of several weeks. Serious adverse events, such as pulmonary edema, are noted to occur early in treatment.


Q: Can people with kidney or liver issues use Behepan?

Caution is advised for patients with impaired kidney function, especially with prolonged administration of the injectable form. This is due to a documented risk of Aluminum accumulation from certain preparations. The official labeling does not contain specific cautions or contraindications regarding liver function impairment.


Q: Does Behepan interfere with birth control pills?

Official information indicates that Oral Contraceptives may lead to a measurable reduction in the serum concentrations of Cobalamins (Vitamin B12). This suggests that the effectiveness of the Vitamin B12 replacement therapy could be lessened. Regulatory guidance directs patients to notify a healthcare provider about all medicines being taken.


Q: What should be done if an interaction with another medicine is suspected?

Regulatory guidance consistently directs patients to notify a doctor or pharmacist about all other medicines, vitamins, or supplements they are using. This information is essential for managing safe and effective use, especially if any suspected interaction or unexpected symptom occurs after starting a new drug.


Q: Can I crush or open the Behepan pill?

The Behepan oral product is officially described as a film-coated tablet. Standard administration guidance for this type of formulation suggests that the tablet should be swallowed whole. Breaking the coating may affect how the medicine is absorbed, and official sources recommend swallowing whole unless instructed otherwise.


Q: How long does it typically take for the effects of Behepan to be noticed?

The noticeable reversal of the physical signs of deficiency, such as anemia and fatigue, can take several weeks of consistent replacement therapy. If neurological involvement is present, recovery is generally observed to be slower and less predictable. Monitoring blood components is an important clinical measure to confirm the therapy is working.


Q: Do any foods or supplements interact with Behepan?

There are no known food-specific interactions listed for Behepan in regulatory documents. However, high-dose Folic Acid is noted as a supplement that may potentially impair the expected blood response to B12 replacement therapy. Regulatory documents recommend informing a healthcare provider about all supplements, as B12 levels are known to be affected by high-dose Folic Acid.


Q: Can Behepan be taken with common over-the-counter pain relievers?

Authoritative sources generally state that the active ingredient, cyanocobalamin, is safe to take alongside common over-the-counter pain relievers. Authoritative sources stress the importance of informing a healthcare professional of all medicines being taken.


Q: What happens if I forget to take a dose of Behepan?

Official guidance for the oral tablet form advises taking the missed dose as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped. It is specified that patients should not take double or extra doses to make up for a missed one. Guidance for injectable forms is managed under specific clinical protocol.


Q: Is Behepan safe to use for older adults?

Vitamin B12 deficiency is very common in older adults, and replacement therapy with cobalamin preparations like Behepan is a standard treatment for this age group. Regulatory information emphasizes that a healthcare professional needs to consider specific physiological factors, such as kidney function, before determining use.


Q: Is there any research on Behepan use during pregnancy?

Behepan is classified by the FDA as Pregnancy Category C. This classification indicates that the medicine should only be used if the prescribing physician determines that the potential benefit justifies the potential risk. Adequate B12 status is considered important for reproductive health.


Q: Has Behepan been studied in children or adolescents?

Official regulatory documents define appropriate pediatric dosing schedules for Behepan. Specific cautions are also outlined for its use in neonates and premature infants, mainly due to the potential risk of toxicity from excipients like benzyl alcohol or Aluminum accumulation.


Q: Does Behepan require any special monitoring or blood tests?

Yes, official clinical guidance often recommends the use of monitoring tests to confirm the medicine is working as intended. These tests typically include measuring blood components like hematocrit, reticulocyte count, and serum B12 levels, both before treatment and during the initial phase of therapy.


Q: Is Behepan known to cause weight gain or loss?

Weight changes are not listed among the commonly or seriously reported adverse reactions for Behepan in official regulatory documents. However, weight loss can be a symptom associated with severe B12 deficiency, which is commonly associated with resolution when the deficiency is successfully corrected.


Q: Does Behepan interact with dairy products?

Authoritative sources do not list any known interactions between the oral or injectable forms of Behepan and dairy products.


Q: Why do some people stop using Behepan?

People may discontinue Behepan use due to various official reasons. These include experiencing intolerable side effects, the existence of known contraindications (such as a hypersensitivity to cobalt), or because their healthcare provider has determined that their necessary course of treatment or intensive phase is complete.


Q: What are the signs of a possible allergic reaction to Behepan?

Signs of a serious allergic reaction may include sudden swelling of the lips, mouth, throat, or tongue; difficulty breathing or wheezing; a tight feeling in the throat; or a rash that is swollen, itchy, or peeling. These symptoms require immediate medical evaluation.


Q: Is it necessary to take Behepan at the exact same time every day?

For the oral tablets, some clinical protocols advise taking the medicine on an empty stomach to optimize its use. While consistent daily timing is generally best practice for daily medicines, the need for an exact time is often a clinical preference. Consistent daily use is generally considered important, especially for long-term maintenance therapy.


Q: What is the typical time frame for follow-up appointments when starting Behepan?

While the precise schedule is determined by the physician, regulatory guidance often requires the monitoring of blood components, with tests often recommended between the 5th and 7th day of initial therapy. Follow-up tests are typically conducted periodically to confirm adequate long-term maintenance therapy.


Q: Is Behepan available without a prescription in some places?

The finished drug product, Behepan (Cobalamins), is regulated as a prescription-only medicine (Rx) in many major regulated markets. However, the underlying active ingredient, Cyanocobalamin, is widely available over-the-counter (OTC) in lower doses as a common dietary supplement.


Q: What is the difference between Behepan and generic versions?

Behepan is a brand-name medicine. Generic versions of its active ingredients, Cyanocobalamin and Hydroxocobalamin, are required to be therapeutically equivalent to their brand-name counterparts. This means they contain the same active ingredients in the same strength and form and are expected to work in the same way.


Q: Why is Behepan sometimes used for different purposes?

Beyond the established treatment of B12 deficiency, research has explored the use of high-dose Vitamin B12 for other indications. Some limited trials have examined its use in managing specific pain conditions, such as low back pain or neuralgia, which are not the primary, officially approved use of the drug.


Q: What are specific symptoms that indicate Behepan is working as intended?

The effectiveness of the medicine is supported by the resolution of symptoms associated with B12 deficiency, such as fatigue, pallor, or neurological issues. Clinical effectiveness is confirmed by a healthcare professional through the measurement of specific blood markers like the reticulocyte count.

How should Behepan be stored and disposed of?

Behepan (Cyanocobalamin) injection must be stored at Controlled Room Temperature, typically 20 C to 25 C, with excursions permitted between 15 C and 30 C. The product must be protected from light and not frozen. Freezing can compromise the integrity of the solution. Always store the medication in its original container to ensure light protection.

Before use, visually inspect the solution for particulate matter or discoloration; if either is present, the product must not be used. For multiple-dose vials, any unused portion must be discarded after 30 days of opening. Unused or expired medication, including ampoules or sharps, should be disposed of in accordance with all local and national regulations to prevent environmental release and accidental exposure. Keep all medications away from children and pets at all times.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Behepan found in:

A-Z Index: